PuSH - Publikationsserver des Helmholtz Zentrums München: Reactivity to N-terminally truncated GAD<sub>65</sub>(96-585) identifies GAD autoantibodies that are more closely associated with diabetes progression in relatives of patients with type 1 diabetes.

Informationen

Hinweise zu Qualitätskriterien von Zeitschriften

Open-Access-Richtlinie der Helmholtz-Gemeinschaft 2016

CC Licencences

Metriken für Publikationen

Navigation

Startseite

English

EVA: Veröffentlichen

Neuer EVA Antrag

Recherche

Erweiterte Suche

Durchblättern nach ...

... HMGU-Autoren/Konsortien

... Organisationsstruktur

... Zeitschriften

... Publikationstypen

... Forschungsdaten

... Arbeitsgruppen

... Erscheinungsjahr

Publikationen im Überblick

Statistik

HGF Fortschrittsbericht

OA Publikationen

Eintragen

Neue Publikation eintragen

Neue Publikation holen aus...

...EVA

Fehlende Publikation melden

Highlights

Suche

Hilfe & Kontakt

Ansprechpartner

Hilfe

Datenschutz

Helmholtz Open Science

Bibliometrische Indikatoren

SHERPA/RoMEO

DOAJ

Export:

Text

Endnote (RIS) BIB

BibTeX

Williams, A.J.* ; Lampasona, V.* ; Wyatt, R.* ; Brigatti, C.* ; Gillespie, K.M.* ; Bingley, P.J.* ; Achenbach, P.

Reactivity to N-terminally truncated GAD₆₅(96-585) identifies GAD autoantibodies that are more closely associated with diabetes progression in relatives of patients with type 1 diabetes.

Diabetes 64, 3247-3252 (2015)

Verlagsversion

DOI

PMC

	Closed

Open Access Green möglich sobald Postprint bei der ZB eingereicht worden ist.

Abstract
Metriken
Zusatzinfos

Autoantibodies to glutamate decarboxylase (GADA) identify individuals at increased risk of type 1 diabetes, but many people currently found GADA positive are unlikely to develop clinical disease. More specific GADA assays are therefore needed. Recent international workshops have shown that reactivity of sera from healthy donors varies according to assay type, and indicated that use of N-terminally truncated GAD65 radiolabels in GADA radiobinding assays is associated with higher specificity. To determine whether a radiobinding assay using radiolabeled GAD65(96-585) identified individuals at higher diabetes risk, samples from recent-onset patients and GADA positive first-degree relatives participating in the Bart's-Oxford type 1 diabetes family study were re-assayed with full-length or N-terminally truncated GAD using the NIDDK harmonized protocol. The sensitivity in patients was the same with both labels, but fewer relatives re-tested positive with truncated GAD. Among relatives who progressed to diabetes, similar proportions were GADA positive when tested with either label, but because of their higher specificity the cumulative risk of diabetes was higher in those with autoantibodies to GAD65(96-585). Autoantibodies to GAD65(96-585) in relatives are more closely associated with diabetes risk than those to full-length GAD, suggesting assays using N-terminally truncated GAD should be used to select participants for intervention trials.

Impact Factor

Scopus SNIP

Web of Science
Times Cited

Scopus
Cited By

Altmetric

8.095

2.027

PuSH - Publikationsserver des Helmholtz Zentrums München

Reactivity to N-terminally truncated GAD65(96-585) identifies GAD autoantibodies that are more closely associated with diabetes progression in relatives of patients with type 1 diabetes.

Reactivity to N-terminally truncated GAD₆₅(96-585) identifies GAD autoantibodies that are more closely associated with diabetes progression in relatives of patients with type 1 diabetes.